Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific Stock Gains From Market Expansion, Innovation

BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.

PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market

The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.

MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin

Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket

TECH registers continued momentum across its Diagnostics & Spatial Biology segment.

DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up

DVA's robust Dialysis patient service revenues drives its third-quarter performance.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Ahead of Big Tech Earnings Releases

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy RMD, CCB, KEX, APOG and LMB.

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock

Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.

ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock

Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.

Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down

Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.

PHG vs. RMD: Which Stock Should Value Investors Buy Now?

PHG vs. RMD: Which Stock Is the Better Value Option?

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

TFX Stock to Gain From Launch of New Vascular Access Devices in Canada

Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.

ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand

RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

Zacks.com featured highlights Leidos, NetApp, ResMed, Trane Technologies and Travelers

Leidos, NetApp, ResMed, Trane Technologies and Travelers have been highlighted in this Screen of The Week article.

ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates

ResMed (RMD) delivered earnings and revenue surprises of 8.37% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

5 Top Dividend Stocks That Promise Substantial Growth

Leidos Holdings, NetApp, ResMed, Trane Technologies and Travelers could be compelling picks for investors looking for dividend stocks.

Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

Is ResMed Stock a Smart Addition to Your Portfolio Right Now?

RMD's robust mask business and efforts to boost its SaaS business are encouraging.

ResMed (RMD) Earnings Expected to Grow: Should You Buy?

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PHG or RMD: Which Is the Better Value Stock Right Now?

PHG vs. RMD: Which Stock Is the Better Value Option?